Cita APA

Allan, J., Shanafelt, T., Wiestner, A., Moreno, C., O'Brien, S., Li, J., . . . Ahn, I. (2022). Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: A pooled analysis from four clinical trials.

Citación estilo Chicago

Allan, JN, T. Shanafelt, A. Wiestner, C. Moreno, SM O'Brien, JL Li, G. Krigsfeld, JP Dean, y IE Ahn. Long-term Efficacy of First-line Ibrutinib Treatment for Chronic Lymphocytic Leukaemia in Patients With TP53 Aberrations: A Pooled Analysis From Four Clinical Trials. 2022.

Cita MLA

Allan, JN, et al. Long-term Efficacy of First-line Ibrutinib Treatment for Chronic Lymphocytic Leukaemia in Patients With TP53 Aberrations: A Pooled Analysis From Four Clinical Trials. 2022.